1349 Stock Overview
Engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.64 |
| 52 Week High | HK$4.42 |
| 52 Week Low | HK$1.70 |
| Beta | 0.30 |
| 1 Month Change | 16.30% |
| 3 Month Change | 10.92% |
| 1 Year Change | 17.86% |
| 3 Year Change | -17.50% |
| 5 Year Change | n/a |
| Change since IPO | -43.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1349 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 2.7% | -1.4% | 1.4% |
| 1Y | 17.9% | 6.6% | 11.3% |
Return vs Industry: 1349 exceeded the Hong Kong Pharmaceuticals industry which returned 8.5% over the past year.
Return vs Market: 1349 exceeded the Hong Kong Market which returned 14.1% over the past year.
Price Volatility
| 1349 volatility | |
|---|---|
| 1349 Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in HK Market | 15.4% |
| 10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1349 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1349's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 923 | Da Jun Zhao | www.fd-zj.com/DesktopModules/HT/chinese/home/Index.aspx |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC that has obtained phase I clinical trial approval for tumors; and HER2 ADC that has carried out phase I clinical study for tumors. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminlevulinic acid hydrochloride, which is in phase II clinical trials for cervical diseases infected by HPV, acne, and actinic keratosis.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Fundamentals Summary
| 1349 fundamental statistics | |
|---|---|
| Market cap | HK$6.87b |
| Earnings (TTM) | HK$43.03m |
| Revenue (TTM) | HK$796.75m |
63.6x
P/E Ratio3.4x
P/S RatioIs 1349 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1349 income statement (TTM) | |
|---|---|
| Revenue | CN¥741.66m |
| Cost of Revenue | CN¥68.63m |
| Gross Profit | CN¥673.03m |
| Other Expenses | CN¥632.98m |
| Earnings | CN¥40.05m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.039 |
| Gross Margin | 90.75% |
| Net Profit Margin | 5.40% |
| Debt/Equity Ratio | 0.2% |
How did 1349 perform over the long term?
See historical performance and comparisonDividends
2.4%
Current Dividend Yield130%
Payout RatioDoes 1349 pay a reliable dividends?
See 1349 dividend history and benchmarks| Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd dividend dates | |
|---|---|
| Ex Dividend Date | Jul 10 2025 |
| Dividend Pay Date | Aug 25 2025 |
| Days until Ex dividend | 61 days |
| Days until Dividend pay date | 107 days |
Does 1349 pay a reliable dividends?
See 1349 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/09 01:16 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Hu | Deutsche Bank |
| Feng Qiang Sun | Guotai Junan International Holdings Limited |
| Xiang Jun | Industrial Securities Co. Ltd. |